TxCell receives latest 1 million-euro milestone payment in OvaSave license agreement
French biotech company TxCell (Euronext Paris: TXCL) has received the latest 1 million-euro milestone payment ($1.13 million) from the OvaSave collaboration option with Trizell.
This payment has come as the result of the first patient enrolment in the Phase IIb trial of TxCell’s lead candidate OvaSave for refractory Crohn’s disease. Topline results are expected at the end of 2016 or early 2017.
The OvaSave Phase IIb study, named CATS29 (Crohn’s And Treg Study), is a multicenter, randomized, double-blind, placebo-controlled, multi-dose and multi-injection, four parallel group study. The trial is conducted in six countries (Austria, Belgium, France, Germany, Italy and United Kingdom) and has been designed to include 160 severe refractory Crohn’s disease patients.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze